Pancreatic cancer is a common malignant tumor of the digestive tract. Due to its high malignancy and rapid progression, it severely affects human health. So how should pancreatic cancer patients be screened? Generally, abdominal ultrasound examination is the primary screening method. Another method is the examination of tumor markers, mainly carcinoembryonic antigen (CEA) and CA19-9. CA19-9 is a tumor marker with relatively high specificity and sensitivity for the diagnosis of pancreatic cancer. Therefore, during physical examinations, we can draw blood to check these tumor markers. If there is a significant increase in CA19-9 or CEA, further examinations of the pancreas, such as ultrasound or CT of the pancreas, should be conducted to further investigate whether there is a tumor in the pancreas.